26
Treatment
Figure 8. Lipid Management in Patients With CCD
Very high-risk includes a history of multiple major ASCVD events or 1 major ASCVD event
and multiple high-risk conditions (Table 10).
* Only when ezetimibe and PCSK9 mAb are deemed insufficient or not tolerated should
bempedoic acid or inclisiran (in place of PCSK9 mAb) be considered to further reduce
LDL-C levels. e effect of bempedoic acid and inclisiran on MACE is being evaluated.
Adapted with permission from Grundy S, et al. op. cit. Copyright 2019 American Heart
Association, Inc. and American College of Cardiolog y Foundation.
High-intensity statin
(Goal: ↓ LDL-C ≥50%)
(1)
Not at Very High Risk
If on maximally
tolerated statin and
LDL-C ≥70 mg/dL,
ezetimibe* may be
reasonable
(2b)
Patients With CCD
Healthy Lifestyle
If high-intensity
statin not tolerated,
moderate-intensity
statin use is
recommended
(1)
